Allion Healthcare (ALLI) Reports Q4 EPS of $0.06
More News related to ALLI
- Law Offices of Brian M. Felgoise, P.C. Announces Investigation on Behalf of Shareholders of Allion Healthcare, Inc.
- Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Allion Healthcare, Inc.
- Holzer Holzer & Fistel, LLC Announces Investigation Into Purchase of Allion Healthcare, Inc.
- Trading Review for Allion Healthcare Inc. Issued by Beacon Equity
- Law Office of Brodsky & Smith, LLC Announces Investigation on Behalf of Shareholders of Allion Healthcare, Inc.
More News related to Earnings
- Highlights From CLWR's Q3 Conference Call: Funding Initiative A Go!, But Investors Worry About Long-Term Outlook
- Arden Group (ARDNA) Posts Q3 EPS of $1.48, Beats Q308 by 18c
- Macy's (M) Shows Good Progress, But Not Good Enough
- Universal Security (UUU) Share Trade Higher on Q2 Earnings Report
- American DG Energy (ADGE) Posts Q3 Loss of $0.01, In-Line with Q308
Allion Healthcare (Nasdaq: ALLI) reports Q4 EPS of $0.06, 1 cent lower than the analyst estimate of $0.07. Revenues for the quarter were $63.6 million, versus the consensus of $62.55 million.
Sees Q1 EPS of $0.04-$0.06, versus the consensus of $0.06.
Allion Healthcare, Inc. provides specialty pharmacy and disease management services to assist patients, healthcare providers, and payors in managing Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) in the United States.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
